|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
IL304526B2
(en)
|
2018-09-29 |
2025-05-01 |
Novartis Ag |
Production of compounds and preparations for inhibiting the activity of SHP2
|
|
CN111647000B
(zh)
*
|
2019-03-04 |
2021-10-12 |
勤浩医药(苏州)有限公司 |
吡嗪类衍生物及其在抑制shp2中的应用
|
|
AR121506A1
(es)
|
2020-03-03 |
2022-06-08 |
Pic Therapeutics Inc |
Inhibidores del eif4e y sus usos
|
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
|
WO2021259077A1
(zh)
*
|
2020-06-22 |
2021-12-30 |
四川科伦博泰生物医药股份有限公司 |
取代吡嗪类化合物,包含其的药物组合物及其用途
|
|
WO2022006780A1
(en)
*
|
2020-07-08 |
2022-01-13 |
Novartis Ag |
Manufacture of compounds and compositions for inhibiting activity of shp2
|
|
ES3040751T3
(en)
|
2020-07-08 |
2025-11-04 |
Novartis Ag |
Manufacture of compounds and compositions for inhibiting the activity of shp2
|
|
EP4208261A1
(en)
|
2020-09-03 |
2023-07-12 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
|
WO2022063190A1
(zh)
*
|
2020-09-23 |
2022-03-31 |
南京明德新药研发有限公司 |
吡嗪硫联苯基类化合物及其应用
|
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
|
CN117642167A
(zh)
*
|
2021-05-05 |
2024-03-01 |
沪亚生物国际有限责任公司 |
Shp2抑制剂单一疗法及其用途
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
CN117677619A
(zh)
*
|
2021-05-05 |
2024-03-08 |
沪亚生物国际有限责任公司 |
包含shp2抑制剂和pd-1抑制剂的联合疗法
|
|
CA3217084A1
(en)
*
|
2021-05-05 |
2022-11-10 |
Farbod Shojaei |
Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
|
|
WO2022235822A1
(en)
*
|
2021-05-05 |
2022-11-10 |
Huabio International, Llc |
Shp2 inhibitor monotherapy and uses thereof
|
|
MX2023012929A
(es)
*
|
2021-05-05 |
2023-11-13 |
Huyabio Int Llc |
Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.
|
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN115340559A
(zh)
*
|
2021-05-12 |
2022-11-15 |
药雅科技(上海)有限公司 |
Shp2磷酸酶杂环类抑制剂的制备及其应用
|
|
TW202244049A
(zh)
*
|
2021-05-12 |
2022-11-16 |
大陸商藥雅科技(上海)有限公司 |
Shp2磷酸酶抑制劑的製備及其應用
|
|
CN115340561A
(zh)
*
|
2021-05-14 |
2022-11-15 |
药雅科技(上海)有限公司 |
Shp2磷酸酶稠环类抑制剂的制备及其应用
|
|
JP7656087B2
(ja)
*
|
2021-05-13 |
2025-04-02 |
中国科学院上海薬物研究所 |
Shp2活性を阻害する複素環化合物、その製造方法および使用
|
|
TW202313041A
(zh)
|
2021-06-09 |
2023-04-01 |
瑞士商諾華公司 |
包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
|
|
JP2024523657A
(ja)
*
|
2021-07-07 |
2024-06-28 |
ヒノバ ファーマシューティカルズ インコーポレイテッド |
ホスファターゼ分解剤の合成及び応用
|
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
US20240374571A1
(en)
|
2021-09-01 |
2024-11-14 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CN116063307B
(zh)
*
|
2021-10-29 |
2025-08-19 |
中国药科大学 |
Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用
|
|
WO2023122938A1
(en)
*
|
2021-12-28 |
2023-07-06 |
Js Innomed Holdings Ltd. |
Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
CN116947867B
(zh)
*
|
2022-04-18 |
2025-12-30 |
上海茂晟康慧科技有限公司 |
一种嘧啶-4(3h)-酮类杂环化合物的重要中间体的制备方法
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN115521305B
(zh)
*
|
2022-09-20 |
2024-11-08 |
中国药科大学 |
Shp2&nampt双靶向化合物及其药物组合物和用途
|
|
US20260137665A1
(en)
|
2022-10-11 |
2026-05-21 |
Aadi Bioscience, Inc. |
Combination therapies for the treatment of cancer
|
|
CN115677661B
(zh)
*
|
2022-10-27 |
2024-04-19 |
中国药科大学 |
杂环硫醚类化合物及其用途和药物组合物
|
|
CN121013721A
(zh)
*
|
2022-11-23 |
2025-11-25 |
沪亚生物国际有限公司 |
包含kras抑制剂和sph2抑制剂的组合疗法
|
|
WO2024125603A1
(zh)
*
|
2022-12-15 |
2024-06-20 |
江苏威凯尔医药科技有限公司 |
Shp2抑制剂及其应用
|
|
WO2024175081A1
(zh)
*
|
2023-02-24 |
2024-08-29 |
深圳真实生物医药科技有限公司 |
Shp2抑制剂化合物及其应用
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
CN121487951A
(zh)
|
2023-04-07 |
2026-02-06 |
锐新医药公司 |
大环ras抑制剂
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
EP4695261A1
(en)
|
2023-04-14 |
2026-02-18 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
WO2025011568A1
(zh)
*
|
2023-07-11 |
2025-01-16 |
勤浩医药(苏州)有限公司 |
用作shp2抑制剂的杂环化合物、包含其的药物组合物及其制备方法和用途
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
KR20260104082A
(ko)
|
2023-09-29 |
2026-07-03 |
디3 바이오 (우씨) 컴퍼니, 리미티드 |
암의 치료에 사용하기 위한 wx-001 또는 그의 유도체와 kras g12c 억제제의 조합물
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN118108707B
(zh)
*
|
2024-02-04 |
2026-06-19 |
中国药科大学 |
吡嗪类化合物及其制备方法、药物组合物和应用
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025242126A1
(zh)
*
|
2024-05-22 |
2025-11-27 |
上海正大天晴医药科技开发有限公司 |
一种药物组合及其应用
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|